We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Inflammatory Bowel Disease Linked to Prostate Cancer

By LabMedica International staff writers
Posted on 18 Dec 2018
About one million men have inflammatory bowel disease in the USA, a common chronic condition that includes Crohn's disease and ulcerative colitis. More...
Epidemiologic studies have noted an association between chronic inflammation and prostate cancer.

Prostate cancer is cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. Prostate cancer is one of the most common types of cancer in men. Usually prostate cancer grows slowly and is initially confined to the prostate gland, where it may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.

A team of urologists and physicians working with the Northwestern University (Evanston, IL, USA) investigated 1,033 men with inflammatory bowel disease (IBD) and a control group of 9,306 men without the disease. They followed the two groups of men for 18 years and found those with IBD were much more likely to have prostate cancer and higher prostate specific antigen (PSA) levels. Follow-up time for all patients was the duration between a patient's first PSA test and last physician encounter. The median age of both case and control groups at first PSA measurement was 53 years, and 74% were white.

The scientists reported that the 5- and 10-year incidences of any prostate cancer (PCa) were 2.8% and 4.4% for cases and 0.25% and 0.65% for controls, respectively. The crude incidences of any PCa were 715 cases in patients with IBD and 167 cases among controls per 100 000 person-years. The incidences of clinically significant PCa were 462 cases in patients with IBD and 115 cases among controls per 100,000 person-years. A total of 27, 221 PSA measurements were assessed for men without IBD and 3,357 for men with IBD. There was a slight trend toward a higher number of PSA tests and higher PSA values among patients with IBD. While PSA estimates were similar in younger patients, age-specific PSA values were significantly higher in patients with IBD in older age, starting at approximately age 60.

The authors concluded that in a retrospective matched-cohort study, men with IBD who underwent PSA-based PCa screening had higher rates of any and clinically significant PCa when compared with age- and race-matched men without IBD. These findings warrant future prospective investigation to better understand the relationship between IBD and PCa.

Shilajit D. Kundu, MD, an associate professor of urology and senior author of the study, said, “These patients may need to be screened more carefully than a man without inflammatory bowel disease. If a man with inflammatory bowel disease has an elevated PSA, it may be an indicator of prostate cancer. Many doctors think when the PSA is elevated, it is just because they have an inflammatory condition. There is no data to guide how we should treat these men.” The study was published on December 4, 2018, in the journal European Urology.

Related Links:
Northwestern University


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.